Compare Biogen Inc (BIIB) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Nvidia Corp — how do they compare? Biogen Inc trades at $193.55 (market cap $28.34B), while Nvidia Corp trades at $210.1 (market cap $5.13T). The key difference: Nvidia Corp is far larger — about 181× Biogen Inc's market cap, and Nvidia Corp pays a 0.47% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NVDA | |
|---|---|---|
Market Cap | $28.34B | $5.13T |
Sector | Health | Technology |
52-Week High | $216.63 | $235.75 |
52-Week Low | $122.68 | $165.17 |
Enterprise Value | $30.62B | $5.06T |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
NVIDIA (NVDA) trades at $210.16, up 3.26% today, reflecting strong momentum amid bullish technical signals and robust fundamentals. The stock exhibits a P/E of 32.43 and a net income margin of 62.97%, with revenue surging to $130.50B in 2025. Recent earnings beats and a consensus analyst price target of $325.86 underscore confidence in its AI leadership and growth trajectory.
Outlook remains positive given accelerating AI demand and earnings strength, though risks include heightened valuations, competitive pressures, and market volatility. The stock presents a compelling growth opportunity for investors aligned with long-term AI trends, supported by solid cash flows and institutional bullishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
